Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.00 and traded as high as $0.97. Xtant Medical shares last traded at $0.95, with a volume of 60,194 shares trading hands.
Xtant Medical Trading Up 5.4 %
The company has a quick ratio of 1.22, a current ratio of 2.82 and a debt-to-equity ratio of 0.34.
Xtant Medical (NYSEAMERICAN:XTNT - Get Free Report) last posted its quarterly earnings data on Monday, April 1st. The medical device company reported ($0.03) EPS for the quarter. Xtant Medical had a return on equity of 1.56% and a net margin of 0.72%. The firm had revenue of $28.11 million during the quarter.
Institutional Investors Weigh In On Xtant Medical
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Sterling Investment Advisors Ltd. bought a new position in shares of Xtant Medical during the 3rd quarter valued at $38,000. AWM Investment Company Inc. bought a new position in shares of Xtant Medical during the 3rd quarter valued at $516,000. Finally, AMH Equity Ltd bought a new position in shares of Xtant Medical during the 3rd quarter valued at $653,000. Hedge funds and other institutional investors own 69.33% of the company's stock.
Xtant Medical Company Profile
(
Get Free Report)
Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.
Further Reading
Before you consider Xtant Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xtant Medical wasn't on the list.
While Xtant Medical currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
